Rize Oncology Inc. (RZONF)

Market Cap	12.12M
Revenue (ttm)	n/a
Net Income	-1.21M
EPS	-0.02
Shares Out	75.74M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	5,000
Average Volume	6,267
Open	0.1600
Previous Close	0.0004
Day's Range	0.1600 - 0.1600
52-Week Range	0.0004 - 0.1600
Beta	n/a
RSI	n/a
Earnings Date	Mar 30, 2026

About Rize Oncology

Rize Oncology Inc., a biopharmaceutical company, focuses on the development of precision gene editing for human therapeutics applications. It develops STS-201, a small-molecule drug for the treatment of soft tissue sarcoma. The company was formerly known as GeneTether Therapeutics Inc. and changed its name to Rize Oncology Inc. in January 2025. Rize Oncology Inc. was incorporated in 2018 and is based in Kelowna, Canada.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2018
• Country: Canada
• Stock Exchange: OTCMKTS
• Ticker Symbol: RZONF